Lycia Therapeutics (LYCA) Stock Price, News & Analysis

Company Overview

Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies.

The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.

Founded in 2019 and based in South San Francisco, California, Lycia has collaborated with Sanofi on the discovery and development of LYTAC-based medicines. I could not verify current leadership details.

Key Stats

• Today's Range: $31.20 to $33.00
• 50-Day Range: N/A
• 52-Week Range: $22.19 to $36.49
• Volume: 189,539 shs
• Average Volume: 471,117 shs
• Market Capitalization: $1.72 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 11/15/2026
• Jefferies Global Healthcare Conference: 11/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:LYCA
• CIK: 1806540
• Web: lyciatx.com
• Phone: (650) 392-3357
• Fax: N/A
• Employees: 65
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 55,030,000
• Free Float: N/A
• Market Cap: $1.72 billion
• Optionable: N/A
• Beta: N/A